Detection of Molecular Variants of BCR-ABL Gene in Bone Marrow and Blood of Patients with Chronic Myeloid Leukemia by Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)

Journal of the Medical Association of Thailand

Volumn 83, Issue 8, 2000, Pages 928-935

  Udomsakdi Auewarakul, Chirayu ^a   U Pratya, Yaowaluk ^a   Boonmoh, Sirikwan ^a   Vatanavicharn, Sumit ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

BCR ABL Gene Variant; Chronic Myeloid Leukemia

Indexed keywords

BCR ABL PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD; BONE MARROW; CASE CONTROL STUDY; CHRONIC MYELOID LEUKEMIA; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETICS; HUMAN; MALE; METHODOLOGY; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THAILAND;

ADULT; BONE MARROW; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THAILAND; TUMOR MARKERS, BIOLOGICAL;

EID: 0034242302     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cline MJ. The molecular basis of leukemia. N Eng J Med 1994; 330:328-36.
2. Metcalf D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature 1989; 339:27-9.
3. Morton CC. Cytogenetics for the Hematologists. In: Handin RI, Lux SE and Stossel TP, editors, Blood: Principles and Practice of Hematology. Philadelphia: JB Lippincott Company; 1995.
4. Heim S, Mitelman F. Cancer Cytogenetics, 2nd edition. New York: Wiley-Liss, Inc, 1995.
5. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632-8.
6. Cross NC, Feng L, Chase A, et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts of chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-36.
7. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.
8. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290.
9. Tkachuk DC, Westbrook CA, Andreeff M, et al. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization. Science 1990; 250: 559-62.
10. Mclaughlin J, Chianese E, Witte O. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987; 84: 6558-62.
11. Daley GQ, vanEtten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome. Science 1990: 247: 824-5.
12. Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-82.
13. Chomozynki P, Sacchi N. Single-step method of RNA isolation. Ann Biochem 1987; 162: 156-9.
14. Kawasaki ES, Clark SS, Coyne MY, et al. Diagnosis of chronic myeloid and acute lymphocytic leukemia by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Nalt Acad Sci USA 1988; 85: 5698-702.
15. Sawyers CL. Chronic myeloid leukemia N Eng J Med 1999; 340: 1330-40.
16. Dobrovic A, Trainor KJ, Morley AA. Detection of the molecular abnormalities in chronic myeloid leukemia by use of the polymerase chain reaction. Blood 1988; 72: 2063-5.
17. Jootar S, Chuncharunee S, Atichartakarn V. Multivariate analysis of prognostic factors in chronic myelogenous leukemia. J Med Assoc Thai 1990; 73: 662-9.
18. Piankitjagum A, Kummalue T, Visudhiphan S, et al. Multivariate analysis of prognostic factors in CML patients. Presented in the Annual Meeting of the Society of Hematology of Thailand, 1992.
19. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-84.
20. Saglio G, Guerrasio A, Rosso C, et al. New type of Bcr/Abl junction in Philadelphia chromosomepositive chronic myelogenous leukemia. Blood 1990; 76:1819-24.
21. Hochhaus A, Reiter A, Skladny H, et al. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome negative chronic myelogenous leukemia. Blood 1996; 88:2236-8.
22. Pane F, Friger F, Sindona M, et al. Neutrophilic-chronic myelogenous leukemia: a distinct disease with a specific molecular marker, BCR-ABL with c3a2 junction. Blood 1996;88: 2410-3.
23. Cortes J, Kantarjian HM, Giralt S, Talpaz M. Natural history and staging of chronic myelogenous leukemia. Bailliere's Clinical Haematology 1997; 10: 277-90.
24. Stein B, Dobrovic A. Relationship between M-BCR breakpoint position in blast crisis and length of chronic phase in chronic myeloid leukemia. Blood 1992; 79:3097.
25. Mills KI, Mackenzie ED, Birnie GD. The site of the breakpoint within the bcr is a prognostic factor in Ph'-positive CML patients. Blood 1988; 72: 1237-40.
26. Ahuja H, Bar-Eli M, Arlin Z, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 1991; 87: 2042-7.
27. Inokuchi K, Futaki M, Yamada T, et al. The relationship between the breakpoints within the bcr gene and thrombopoiesis of Philadelphia-positive chronic myelocytic leukemia. Leuk Res 1991; 15:1067-72.
28. Oplaka B, Wandl UB, Kloke O, et al. No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia. Blood 1992; 80: 1854-5.
29. Rozman C, Urbano IA, Cervantes F, et al. Analysis of the clinical relevance of the breakpoint location within the M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia. Leukemia 1995; 9: 1104-8.
30. Van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 1989; 58: 69-78.